Search
Search Funnelback University
- Refined by:
- Date: Past month
Did you mean economiespast |u:www.enterprise.cam.ac.uk?
Your query has been expanded to Economics test |u:www.enterprize.cam.ac.uk. Search for Economics test |u:www.enterprise.cam.ac.uk instead.
31 -
36 of
36
search results for Economics test |u:www.enterprise.cam.ac.uk or Economics test |u:www.enterprize.cam.ac.uk
where 2
match all words and 34
match some words.
Results that match 1 of 2 words
-
CellCentric raises $26m to take first-in-class p300/CBP inhibitor…
https://www.enterprise.cam.ac.uk/news/cellcentric-raises-26-million-to-take-first-in-class-p300cbp-inhibitor-into-the-clinic/22 Feb 2023: The funds will be used to test the novel p300/CBP inhibitor in late stage, treatment-resistant prostate cancer (up to Phase IIb). -
University of Cambridge breaks its early stage investment record for…
https://www.enterprise.cam.ac.uk/news/university-of-cambridge-breaks-its-early-stage-investment-record-for-third-consecutive-year/22 Feb 2023: This was the fourth year of operation for the Enterprise Fund, which was announced as part of the SEIS programme in the government’s 2012 budget, established to stimulate economic growth. -
University of Cambridge breaks its early stage investment record for…
https://www.enterprise.cam.ac.uk/news/university-of-cambridge-breaks-its-early-stage-investment-record-for-the-fourth-consecutive-year/22 Feb 2023: This was the fourth year of operation for the Enterprise Fund, which was announced as part of the SEIS programme in the government’s 2012 budget, established to stimulate economic growth. -
Cambridge joins consortium to launch £40 million Apollo fund to drive …
https://www.enterprise.cam.ac.uk/news/cambridge-enterprise-joins-consortium-world-leading-uk-universities-global-pharmaceutical-companies-launch-40-million-fund-drive-therapeutic-innovation/22 Feb 2023: valuable proposition for any academic or company that wants to see early stage ground breaking therapeutic technology progress to the clinic for patient benefit and economic return. ... for patient benefit and economic return.”. -
Portfolio company Mission Therapeutics awarded research grant from…
https://www.enterprise.cam.ac.uk/news/cambridge-enterprise-portfolio-company-mission-therapeutics-awarded-research-grant-from-the-michael-j-fox-foundation/22 Feb 2023: The objective of the research collaboration with Prof Wade-Martins is to test Mission’s potent and selective USP30 inhibitors in a range of disease models—induced Pluripotent Stem Cells ... There is no objective test, or biomarker, for Parkinson’s -
New agreement with Cambridge spin-out PredictImmune lets SLE join…
https://www.enterprise.cam.ac.uk/news/new-agreement-with-university-spin-out-predictimmune-allows-product-pipeline-to-include-systemic-lupus-erythematosus/22 Feb 2023: As with IBD, patients with SLE can present with a variable disease course, and it is this variability that makes it an ideal choice for the development of a prognostic test
Refine your results
clear all
Date
Search history
Recently clicked results
Recently clicked results
Your click history is empty.
Recent searches
- Economics middle test (25) · moments ago
Recent searches
Your search history is empty.